Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Applied Dna Sciences Inc (APDN)

Applied Dna Sciences Inc (APDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,168
  • Shares Outstanding, K 435
  • Annual Sales, $ 3,430 K
  • Annual Income, $ -6,990 K
  • EBIT $ -13 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.07
  • Price/Sales 0.66
  • Price/Cash Flow N/A
  • Price/Book 0.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -265.50
  • Growth Rate Est. (year over year) +476.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.38 +14.84%
on 07/02/25
5.65 -10.97%
on 07/08/25
-0.09 (-1.76%)
since 06/16/25
3-Month
4.37 +15.23%
on 05/30/25
14.23 -64.66%
on 04/22/25
-6.97 (-58.08%)
since 04/16/25
52-Week
4.37 +15.23%
on 05/30/25
2,655.00 -99.81%
on 08/23/24
-324.97 (-98.48%)
since 07/16/24

Most Recent Stories

More News
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements

STONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received written...

APDN : 5.03 (+1.00%)
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

- Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth -

APDN : 5.03 (+1.00%)
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO

APDN : 5.03 (+1.00%)
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August

STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resume...

APDN : 5.03 (+1.00%)
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17

STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, is rescheduling...

APDN : 5.03 (+1.00%)
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect...

APDN : 5.03 (+1.00%)
Applied DNA Sciences: Fiscal Q2 Earnings Snapshot

Applied DNA Sciences: Fiscal Q2 Earnings Snapshot

APDN : 5.03 (+1.00%)
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues -

APDN : 5.03 (+1.00%)
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3

STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release...

APDN : 5.03 (+1.00%)
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

- Pivot to U.S.-based Supply Chain for Critical Input Materials Completed -

APDN : 5.03 (+1.00%)

Business Summary

Applied DNA Sciences, Inc. provides proprietary DNA-embedded biotechnology security solutions, using non-human DNA, that verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion. They develop, market,...

See More

Key Turning Points

3rd Resistance Point 5.45
2nd Resistance Point 5.30
1st Resistance Point 5.17
Last Price 5.03
1st Support Level 4.89
2nd Support Level 4.74
3rd Support Level 4.61

See More

52-Week High 2,655.00
Fibonacci 61.8% 1,642.46
Fibonacci 50% 1,329.68
Fibonacci 38.2% 1,016.91
Last Price 5.03
52-Week Low 4.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar